PubMed Health⌕ Search

Biomedical subjects

E L Gurwich

Publications and source records attributed to E L Gurwich.

9 recordsLinked to original sources
PubMed1984

Unbound plasma salicylate concentration in rheumatoid arthritis patients.

This study was designed to investigate the relationship of free plasma salicylate to total plasma salicylate and to determine the clinical utility of monitoring the free plasma salicylate concentration. Analysis of 46 patient samples indicated a close correlation between the free and total plasma concentration and that there is no additional advantage to monitoring the free plasma salicylate concentration. Also this study re-emphasizes the unique pharmacokinetic characteristics of salicylate, whereby the amount of free plasma salicylate increases disproportionately with increased total plasma salicylate concentration.

Adult↗
PubMed1982

A first-phase quality assurance program for intravenous admixture aseptic technique.

Results of initial departmental quality assurance audits revealed noncompliance with the intravenous admixture service criteria concerning aseptic technique. In order to better assess this problem, a quality assurance program for aseptic technique was developed. The criteria consisted of 16 characteristics and/or functions that are indicative of aseptic technique. An audit of 13 technicians revealed a number of problems (noncompliance) related to aseptic technique. An educational program was developed and implemented on an individual basis. A reaudit two to four weeks later revealed compliance with the aseptic technique criteria. This study indicates that the audit method is effective in determining compliance to the aseptic technique criteria and standards.

Antisepsis↗
PubMed1980

Audit of an oral anticoagulant teaching program.

Quality assurance criteria for a pharmacist-conducted oral anticoagulant teaching program were studied. The teaching program involved the presentation of descriptive diagrams accompanied by a reinforcing explanation given by a pharmacist. Topics discussed included clotting, warfarin therapy, diet and drug interactions. An audit, consisting of a pretest and posttest, was developed to measure patient knowledge as a measurement of the program's effectiveness. Forty ambulatory patients participated in the study over a three-month period. Before instruction, only five patients were adequately knowledgeable about all of the information components. After instruction, this number increased to 20 patients, and all 40 patients had a better knowledge of each topic. The audit revealed that the program's standards were not completely appropriate and that other methods of program delivery must be evaluated and implemented.

Anticoagulants↗
PubMed1978

Gentamicin-cephalothin drug reaction.

A case report describing the occurrence of nephrotoxicity in a 26-year-old black male with sickle cell anemia after concurrent i.v. administration of gentamicin sulfate and cephalothin sodium is presented. Cephalothin 1 g.i.v. every six hours was given for three days for a Klebsiella infection demonstrated by urine and blood culture to be cephalosporin sensitive. Cephalothin was then discontinued and gentamicin, after an i.v. loading dose of 2.6 mg/kg, was given for 14 days in a dosage of 1.3 mg/kg every eight hours. After cultures of pus aspirated from the right thigh demonstrated Klebsiella, 2 g of cephalothin was administered i.v. every six hours and gentamicin sulfate was discontinued. Gentamicin therapy was reinstituted two days later, at a dosage of 5 mg/kg/day. The gentamicin-cephalothin therapy was continued for nine days. The gentamicin dosage interval was increased from every eight to every 16 hours when serum creatinine and gentamicin levels became elevated. Gentamicin was discontinued entirely two days later because serum gentamicin levels were not decreasing. Previous case reports and studies of nephrotoxicity associated with concurrent gentamicin-cephalothin therapy are reviewed. Pharmacists should be alert to the possible increased incidence of nephrotoxicity occurring with concurrent genticin-cephalothin therapy.

Adult↗